| Name | Title | Contact Details |
|---|
Elementary is a company specializing in advanced machine vision inspection, utilizing AI and automation to enhance manufacturing processes. Founded in mid-2017 by experienced professionals from various sectors, the company aims to develop a new generation of manufacturing products that rely on computer vision and AI. Their platform automates traceability scans and integrates AI, machine vision, and automation into production lines. This approach focuses on improving quality, traceability, and root cause analyses, making manufacturing processes more efficient. Elementary emphasizes a human-in-the-loop strategy, enhancing collaboration between humans and machines to optimize working conditions and outcomes. Based in Los Angeles, California, Elementarys team includes roboticists, computer scientists, designers, and engineers. The company has attracted significant funding, including a $30 million Series B round led by Tiger Global, to support its innovative solutions in manufacturing. Their technology is utilized by notable clients across various industries, including Toyota in the automotive sector.
We offer surplus lines products to California agents, primarily homeowners (HO3) and landlord (DF3) policies. Please visit our website for information on how to become appointed.
BHS Corrugated – leading provider of solutions for the corrugated industry BHS Corrugated is the leading provider of solutions for the corrugated industry with 3,000 employees at headquarters in Weiherhammer, Germany as well as in more than 20 countries. As Lifecycle Partner, BHS Corrugated is consistently strong across the entire product and service range: from development and production, to installation and maintenance, to a variety of innovative Lifecycle Service solutions in the areas of corrugating rolls, individual machines, complete corrugators, industry 4.0, logistics and soon to come digital print in- and outside the corrugator. Significant aspects of digitalization, primarily regarding the optimization of process parameters and increasing degrees of automation and production efficiency, have been central issues of BHS Corrugated for many years. To meet the requirements of its customers as precisely as possible and to be always state-of-the-art, BHS Corrugated reinvests close to 5 percent of its turnover in research and development. In addition to its core business, BHS Corrugated supports different social projects, for example the familys own foundation "Angels for Children" or the "Lars und Christian Engel Stiftung (LUCE Trust)", which supports technological and economic development in the region. Contact: BHS Corrugated Maschinen- und Anlagenbau GmbH Paul-Engel-Str. 1 92729 Weiherhammer info@bhs-world.com Tel. +49 9605 919 0 bhs-world.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.